MOL 126
Latest Information Update: 08 Sep 1999
Price :
$50 *
At a glance
- Originator Molecumetics
- Class Antithrombotics
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 08 Sep 1999 Discontinued-Preclinical for Thrombosis in USA (Unknown route)
- 29 Jan 1998 Preclinical development for Thrombosis in USA (Unknown route)
- 29 Sep 1997 New profile